460,704 Shares in Stevanato Group S.p.A. $STVN Bought by Fideuram Intesa Sanpaolo Private Banking S.P.A.

Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in Stevanato Group S.p.A. (NYSE:STVN) in the 4th quarter, HoldingsChannel.com reports. The firm bought 460,704 shares of the company’s stock, valued at approximately $9,269,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. TimesSquare Capital Management LLC lifted its position in Stevanato Group by 7.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 3,500,321 shares of the company’s stock worth $70,426,000 after purchasing an additional 232,645 shares during the period. Van Berkom & Associates Inc. lifted its position in Stevanato Group by 55.4% in the fourth quarter. Van Berkom & Associates Inc. now owns 5,617 shares of the company’s stock worth $113,000 after purchasing an additional 2,002 shares during the period. Jennison Associates LLC lifted its position in Stevanato Group by 13.7% in the fourth quarter. Jennison Associates LLC now owns 1,772,896 shares of the company’s stock worth $35,671,000 after purchasing an additional 213,602 shares during the period. Farther Finance Advisors LLC lifted its position in Stevanato Group by 391.4% in the fourth quarter. Farther Finance Advisors LLC now owns 8,324 shares of the company’s stock worth $167,000 after purchasing an additional 6,630 shares during the period. Finally, Cooper Investors PTY Ltd. lifted its position in Stevanato Group by 17.8% in the fourth quarter. Cooper Investors PTY Ltd. now owns 695,245 shares of the company’s stock worth $13,988,000 after purchasing an additional 104,937 shares during the period.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Citigroup reduced their target price on Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Morgan Stanley dropped their price objective on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a research note on Friday, March 6th. Wall Street Zen lowered Stevanato Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings lowered Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 11th. Finally, KeyCorp dropped their price objective on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold”.

Stevanato Group Stock Performance

Shares of NYSE:STVN opened at €17.49 on Wednesday. Stevanato Group S.p.A. has a twelve month low of €12.89 and a twelve month high of €28.00. The firm has a market cap of $5.30 billion, a PE ratio of 29.64, a price-to-earnings-growth ratio of 1.64 and a beta of 0.75. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.11 and a current ratio of 1.63. The business has a fifty day moving average of €15.53 and a 200-day moving average of €18.28.

Stevanato Group (NYSE:STVN) last announced its earnings results on Friday, May 8th. The company reported €0.11 earnings per share for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). Stevanato Group had a net margin of 11.76% and a return on equity of 10.27%. The business had revenue of €273.57 million during the quarter. During the same period in the previous year, the business posted $0.10 EPS. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. On average, equities research analysts predict that Stevanato Group S.p.A. will post 0.68 EPS for the current fiscal year.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.